Recent advances regarding tumor microenvironment and immunotherapy in hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the liver, with poor prognosis and high mortality. Traditional treatments for patients with HCC have shown poor efficacy especially for advanced liver cancer. Compared with other organs, the liver has more natural immune cells such as Kupffer cells, natural killer cells and natural killer T cells. Immunotherapy for liver cancer has become the focus in current research. The theoretical basis of immunotherapy rests on immune tolerance and suppression in the tumor microenvironment. Common immunotherapy methods include vaccines, cytokines, adoptive cell therapies, immune checkpoint inhibitors, and oncolytic viruses. Compared with traditional treatment, immunotherapy can enhance the body’s immune function, delay tumor progression, and prolong survival. This article reviews the HCC microenvironment and immunotherapy both in the clinical and basic research aspects.

Keywords

Immunotherapy / hepatocellular carcinoma / microenvironment / immune

References

[1] Akinyemiju T,Ahmed M,Alemayohu MA.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015..JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[2] Forner A,Bruix J.Hepatocellular carcinoma..Lancet2018;391:1301-14

[3] Fujimoto A,Abe T,Hosoda F.Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators..Nat Genet2012;44:760-4

[4] Hilmi M.Immune therapy for liver cancers..Cancers (Basel)2019;12:77 PMCID:PMC7016834

[5] Gao B,Tian Z.Liver: an organ with predominant innate immunity..Hepatology2008;47:729-36

[6] Shalapour S,Bastian IN,Burt AD.Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity..Nature2017;551:340-5 PMCID:PMC5884449

[7] Movahedi K,Gysemans C,Stange G.Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes..Cancer Res2010;70:5728-39

[8] Mantovani A.The interaction of anticancer therapies with tumor-associated macrophages..J Exp Med2015;212:435-45 PMCID:PMC4387285

[9] Ye YC,Lu YT,Yang Y.NOTCH signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma..Cancer Res2019;79:4160-72

[10] Zhu F,Chen S,Zhao Y.Tumor-associated macrophage or chemokine ligand CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma..Med Oncol2016;33:17

[11] Zhou SL,Hu ZQ,Wang Z.Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib..Gastroenterology2016;150:1646-58.e17

[12] Li ZQ,Zeng QL,Hu YS.p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma..Cancer Med2020;9:711-23 PMCID:PMC6970059

[13] Zhou J,Pan W,Li L.Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients..Int J Cancer2009;125:1640-8

[14] Sharma S,David P,Vyas A.CD4⁺CD25⁺CD127(low) regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma..Front Immunol2015;6:49 PMCID:PMC4341117

[15] Zhu Y,Xu D,Zhang Z.Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade..Gut2019;68:1653-66

[16] Kuang DM,Zhao Q,Chen MS.Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells..Hepatology2010;51:154-64

[17] Fu Y,Zeng S.From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma..J Exp Clin Cancer Res2019;38:396 PMCID:PMC6734524

[18] Darvishi B,Ghadirian R,Farahmand L.Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies..Life Sci2019;217:34-40

[19] Chang CP,Lee PH.Targeting NFKB by autophagy to polarize hepatoma-associated macrophage differentiation..Autophagy2013;9:619-21 PMCID:PMC3627680

[20] Nicolas-Avila JA,Hidalgo A.Neutrophils in homeostasis, immunity, and cancer..Immunity2017;46:15-28

[21] Andzinski L,Stahnke S,Gereke M.Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human..Int J Cancer2016;138:1982-93

[22] Michaeli J,Mishalian I,Levy L.Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFalpha and NO-dependent mechanism, promoting a tumor-supportive environment..Oncoimmunology2017;6:e1356965 PMCID:PMC5674962

[23] Margetts J,Chan SL,Chan KCA.Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?.Br J Cancer2018;118:248-57 PMCID:PMC5785742

[24] Mano Y,Yamashita Y,Tsujita E.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis..Ann Surg2013;258:301-5

[25] Zhou SL,Hu ZQ,Wang Z.Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib..Gastroenterology2016;150:1646-58.e17

[26] Zhou SL,Hu ZQ,Zhou ZJ.A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression..Hepatology2019;70:1214-30

[27] Robinson MW,O’Farrelly C.Liver immunology and its role in inflammation and homeostasis..Cell Mol Immunol2016;13:267-76 PMCID:PMC4856809

[28] Sundstrom P,Ahlmanner F,Wong JSB.Tumor-infiltrating mucosal-associated invariant T (MAIT) cells retain expression of cytotoxic effector molecules..Oncotarget2019;10:2810-23 PMCID:PMC6497460

[29] Gajewski TF,Fu YX.Innate and adaptive immune cells in the tumor microenvironment..Nat Immunol2013;14:1014-22 PMCID:PMC4118725

[30] Parodi M,Cangelosi D,Balsamo M.Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration..Front Immunol2018;9:2358 PMCID:PMC6232835

[31] Sheppard S,Guedes J.The paradoxical role of NKG2D in cancer immunity..Front Immunol2018;9:1808 PMCID:PMC6099450

[32] Chambers AM,Matosevic S.Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells..Front Immunol2018;9:2517 PMCID:PMC6235907

[33] Dengler VL,Espinosa JM.Transcriptional regulation by hypoxia inducible factors..Crit Rev Biochem Mol Biol2014;49:1-15 PMCID:PMC4342852

[34] Vujanovic L,Pardee AD,Tsung A.Tumor-derived alpha-fetoprotein directly drives human natural killer-cell activation and subsequent cell death..Cancer Immunol Res2017;5:493-502

[35] Sun C,Zhang C.NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma..Cell Mol Immunol2015;12:292-302 PMCID:PMC4654321

[36] Cai L,Zhou L,Fu J.Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients..Clin Immunol2008;129:428-37

[37] Fan Y,Rao J,Zhang F.YAP-1 promotes tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2 transcription..Cell Physiol Biochem2017;41:1189-98

[38] Wu R,Deng X,Hao S.Enhanced alleviation of aGVHD by TGF-beta1-modified mesenchymal stem cells in mice through shifting MPhi into M2 phenotype and promoting the differentiation of Treg cells..J Cell Mol Med2020;24:1684-99 PMCID:PMC6991663

[39] Gao Q,Fan J,Wang XY.Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection..J Clin Oncol2007;25:2586-93

[40] Fu J,Liu Z,Zhao P.Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients..Gastroenterology2007;132:2328-39

[41] Yang XH,Ichida T,Sugahara S.Increase of CD4⁺ CD25⁺ regulatory T-cells in the liver of patients with hepatocellular carcinoma..J Hepatol2006;45:254-62

[42] Guo CL,Cheng W,Li JB.Expression of Fas/FasL in CD8⁺ T and CD3⁺ Foxp3⁺ Treg cells--relationship with apoptosis of circulating CD8⁺ T cells in hepatocellular carcinoma patients..Asian Pac J Cancer Prev2014;15:2613-8

[43] Huang CY,Liao W,Li YQ.Transforming growth factor beta is a poor prognostic factor and inhibits the favorable prognostic value of CD8⁺ CTL in human hepatocellular carcinoma..J Immunother2017;40:175-86

[44] Sun Z,Yang K,Cao S.A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control..Nat Commun2019;10:3874 PMCID:PMC6713724

[45] Motz GT,Wang LP,Lastra RR.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors..Nat Med2014;20:607-15 PMCID:PMC4060245

[46] Han Y,Yang Y,Gu Y.Human CD14⁺ CTLA-4⁺ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma..Hepatology2014;59:567-79

[47] Shedlock DJ.Requirement for CD4 T cell help in generating functional CD8 T cell memory..Science2003;300:337-9

[48] Borst J,Babala N,Kastenmuller W.CD4(+) T cell help in cancer immunology and immunotherapy..Nat Rev Immunol2018;18:635-47

[49] Benites BD,Saad STO.Small particles, big effects: the interplay between exosomes and dendritic cells in antitumor immunity and immunotherapy..Cells2019;8:1648 PMCID:PMC6952774

[50] Choi YJ,Park YS,Yang KM.EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells..PloS one2018;13:e0190638 PMCID:PMC5752035

[51] Dou L,Chen YF,Chen XP.Erratum: hepatic dendritic cells, the tolerogenic liver environment, and liver disease..Semin Liver Dis2018;38:298

[52] Palucka K.Dendritic-cell-based therapeutic cancer vaccines..Immunity2013;39:38-48 PMCID:PMC3788678

[53] Sun K,Zhang Y.Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma..Cell Mol Immuno2006;3:197-203

[54] Chen YX,Ling GS,Sun BS.A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10..J Immunol2007;179:6009-15

[55] Beckebaum S,Chen X,Frilling A.Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets..Clin Cancer Res2004;10:7260-9

[56] Perez CR.Engineering dendritic cell vaccines to improve cancer immunotherapy..Nat Commun2019;10:5408 PMCID:PMC6881351

[57] Peng M,Wang Y,Zhang Y.Neoantigen vaccine: an emerging tumor immunotherapy..Mol Cancer2019;18:128 PMCID:PMC6708248

[58] Gabrilovich DI.Myeloid-derived suppressor cells as regulators of the immune system..Nat Rev Immunol2009;9:162-74 PMCID:PMC2828349

[59] Xu M,Song J,Lu S.Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer..Exp Cell Res2017;351:142-49

[60] Guha P,Darpolor J,Lima M.STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells..Oncogene2019;38:533-48

[61] Sun H,Tian Y,Zhou J.An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma..Nat Commun2018;9:5214 PMCID:PMC6283830

[62] Li B,Huang N,Wang P.CCL9/CCR1 induces myeloidderived suppressor cell recruitment to the spleen in a murine H22 orthotopic hepatoma model..Oncol Rep2019;41:608-18

[63] Zhou J,Sun H,Xu L.Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy..Gut2018;67:931-44 PMCID:PMC5961939

[64] Limagne E,Thibaudin M,Truntzer C.Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients..Oncoimmunology2019;8:e1564505 PMCID:PMC6422400

[65] Hoechst B,Ormandy L,Zhao F.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor..Hepatology2009;50:799-807 PMCID:PMC6357774

[66] Hu CE,Zhang RD,Huang GJ.Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function..Scand J Gastroenterol2011;46:156-64

[67] Wu CJ,Lee IJ,Lu LS.Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment..Oncoimmunology2018;7:e1477459 PMCID:PMC6140549

[68] Liu M,Liu X,Yang W.Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma..Gut2020;69:365-79

[69] Kang N,Shah VH.Hepatic stellate cells: partners in crime for liver metastases?.Hepatology2011;54:707-13 PMCID:PMC3145026

[70] Amann T,Spruss T,Gabele E.Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma..Cancer Sci2009;100:646-53

[71] Neaud V,Guirouilh J,Balabaud C.Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor..Hepatology1997;26:1458-66

[72] Amin DN,Bielenberg DR.Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors..Cancer Res2006;66:2173-80

[73] Rolny C,Magnusson P,Jakobsson L.Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation..Blood2006;108:1877-86

[74] Limmer A,Kurts C,Reiss Y.Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance..Nat Med2000;6:1348-54

[75] Bilzer M,Gerbes AL.Role of Kupffer cells in host defense and liver disease..Liver Int2006;26:1175-86

[76] Ramaiah SK.Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer..Toxicol Sci2008;103:4-13

[77] Cressman DE,DeAngelis RA,Furth EE.Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice..Science1996;274:1379-83

[78] Zhang M,Han Y.Apoptotic cells attenuate fulminant hepatitis by priming Kupffer cells to produce interleukin-10 through membrane-bound TGF-beta..Hepatology2011;53:306-16

[79] Hong Y,Guo ZS,Pang J.Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma..Hepatology2014;59:1448-58 PMCID:PMC4151349

[80] Bei R.Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine..Curr Mol Med2011;11:564-81

[81] Nakagawa H,Kobayashi E,Hamana H.Association between high-avidity T-cell receptors, induced by alpha-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma..Gastroenterology2017;152:1395-406.e10

[82] Zhang W,Wu Y,Wang Y.Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice..Biochem Biophys Res Commun2008;376:10-4

[83] Chen K,Zhao H,Ge Y.XCL1/Glypican-3 fusion gene immunization generates potent antitumor cellular immunity and enhances anti-PD-1 efficacy..Cancer Immunol Res2020;8:81-93

[84] Sawada Y,Nobuoka D,Kuronuma T.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival..Clin Cancer Res2012;18:3686-96

[85] Nakayama J,Tahara E,Ito K.Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas..Nat Genet1998;18:65-8

[86] Harrington L,McPhail T,Yeung DS.Human telomerase contains evolutionarily conserved catalytic and structural subunits..Genes Dev1997;11:3109-15 PMCID:PMC316744

[87] Mizukoshi E,Marukawa Y,Yamashita T.Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma..Hepatology2006;43:1284-94

[88] Mizukoshi E,Kitahara M,Arai K.Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma..Cancer Lett2015;364:98-105

[89] Bricard G,Martinet O,Halkic N.Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma..J Immunol2005;174:1709-16

[90] Dhodapkar MV,Krasovsky J,Bhardwaj N.Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells..J Exp Med2001;193:233-8 PMCID:PMC2193335

[91] Schuler-Thurner B,Berger TG,Ebner S.Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells..J Exp Med2002;195:1279-88 PMCID:PMC2193752

[92] Chen C,Zhang YT,Zhou N.Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis..Cytotherapy2018;20:975-89

[93] Lu Z,Jing R,Rao Q.Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models..J Hepatol2017;67:739-48

[94] Wilgenhof S,Heirman C,Lucas S.Phase Ii study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma..J Clin Oncol2016;34:1330-8

[95] Lee JH,Lee M,Song JS.A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma..Br J Cancer2015;113:1666-76 PMCID:PMC4702003

[96] Nemunaitis J,Orr D,Magee M.Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG) in advanced cancer of the liver..Oncology2014;87:21-9

[97] Pexa-Vec/Nexavar Combination Fails Phase III Trial in Liver Cancer. Available from: https://www.genengnews.com/news/pexa-vec-nexavar-combination-fails-phase-iii-trial-in-liver-cancer/ [Last accessed on 21 Apr 2020]

[98] Mahipal A,Kommalapati A,Kim R.Immunotherapy in hepatocellular carcinoma: is there a light at the end of the tunnel?.Cancers (Basel)2019;11:1078 PMCID:PMC6721326

[99] Yoo SY,Kang DH.Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma..Oncotarget2017;8:71489-99 PMCID:PMC5641064

[100] Ady JW,Mojica K,Belin LJ.Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently..Surgery2014;156:263-9 PMCID:PMC4216725

[101] Wang J,Zeng W,Zeng M.Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta..Cancer Cell Int2014;14:83 PMCID:PMC4213511

[102] Twumasi-Boateng K,Kwok YYE,Nelson BH.Oncolytic viruses as engineering platforms for combination immunotherapy..Nat Rev Cancer2018;18:419-32

[103] Haanen JB.Immune checkpoint inhibitors..Prog Tumor Res2015;42:55-66

[104] Meng X,Teng F,Yu J.Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy..Cancer Treat Rev2015;41:868-76

[105] Sangro B,de la Mata M,Garralda E.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C..J Hepatol2013;59:81-8

[106] Zhang M,Zhao W,Yan LX.VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma..BMC Cancer2018;18:511 PMCID:PMC5932869

[107] Prieto J,Sangro B.Immunological landscape and immunotherapy of hepatocellular carcinoma..Nat Rev Gastroenterol Hepato2015;12:681-700

[108] Li H,Tao K,Zheng Q.Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma..Hepatology2012;56:1342-51

[109] Woo SR,Goldberg MV,Selby M.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape..Cancer Res2012;72:917-27 PMCID:PMC3288154

[110] Krummel MF.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation..J Exp Med1995;182:459-65 PMCID:PMC2192127

[111] van der Merwe PA,Daenke S,Davis SJ.CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics..J Exp Med1997;185:393-403 PMCID:PMC2196039

[112] Qureshi OS,Nakamura K,Manzotti C.Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4..Science2011;332:600-3 PMCID:PMC3198051

[113] Duffy AG,Makorova-Rusher O,Wedemeyer H.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma..J Hepatol2017;66:545-51 PMCID:PMC5316490

[114] Keir ME,Freeman GJ.PD-1 and its ligands in tolerance and immunity..Annu Rev Immunol2008;26:677-704

[115] Okazaki T.PD-1 and PD-1 ligands: from discovery to clinical application..Int Immunol2007;19:813-24

[116] Bardhan K,Boussiotis VA.The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation..Front Immunol2016;7:550 PMCID:PMC5149523

[117] Iwai Y,Tanaka Y,Honjo T.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade..Proc Natl Acad Sci U S A2002;99:12293-7 PMCID:PMC129438

[118] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[119] Kudo M,Santoro A,Gracian AC.Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status..J Clin Oncol2019;37:327-2

[120] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[121] Finn RS,Merle P,Bouattour M.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial..J Clin Oncol2020;38:193-202

[122] Stein S,Lee MS,Hernandez S.Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)..J Clin Oncol2018;36:4074-74

[123] Xiang J,Sun H,Zhang C.Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of PD-L1 in Hepatocellular Carcinoma Cells..Gastroenterology2020;158:664-78.e24

[124] Nakamoto N,Shaked A,Valiga ME.Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade..PLoS Pathog2009;5:e1000313 PMCID:PMC2642724

[125] Aregay A,Deterding K,Dietz J.Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8⁺ T cell responses..J Hepatol2019;71:889-99

[126] Stein S,Lee MS,Hernandez S.Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)..J Clin Oncol2018;36:

[127] Baxi S,Gennarelli RL,Wang Z.Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis..BMJ2018;360:k793 PMCID:PMC5851471

[128] Moslehi JJ,Sosman JA,Johnson DB.Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis..Lancet2018;391:933 PMCID:PMC6668330

[129] Chmielewski M,Abken H.Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells..Front Immunol2013;4:371 PMCID:PMC3822734

[130] Ramos CA.Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy..Expert Opin Biol Ther2011;11:855-73 PMCID:PMC3107373

[131] Gao HP,Tu H,Jiang H.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma..Clin Cancer Res2014;20:6418-28

[132] Liu Y,Shi B,Wang Y.Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma..J Immunol2019;203:198-207

[133] Chen C,Jiang H,Gao H.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma..Cancer Immunol Immunother2017;66:475-89

[134] Zhai B,Gao H,Jiang H.A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3⁺ hepatocellular carcinoma (r/r GPC3⁺ HCC)..J Clin Oncol2017;35:3049-49

[135] MacKay M,Rub J,Khunte M.The therapeutic landscape for cells engineered with chimeric antigen receptors..Nat Biotechnol2020;38:233-44

[136] Rafiq S,Brentjens RJ.Engineering strategies to overcome the current roadblocks in CAR T cell therapy..Nat Rev Clin Oncol2020;17:147-67

[137] Gao XC,Guo N,Xu LX.Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy..Front Immunol2017;8:774 PMCID:PMC5498561

[138] Mata-Molanes JJ,Jimenez BV,Masllorens AB.Cancer immunotherapy with cytokine-induced killer cells..Target Oncol2017;12:289-99

[139] Pan QZ,Dan JQ,Li YQ.A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma..Sci Rep2015;5:9202 PMCID:PMC4361845

[140] Lee JH,Lim YS,Song TJ.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma..Gastroenterology2015;148:1383-91.e6

[141] Huang ZM,Li S,Zhou QM.Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients..J Immunother2013;36:287-93

[142] Yu X,Liu L,Ren B.A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma..J Clin Immunol2014;34:194-203

[143] Yu SJ,Heinrich B,Sandhu M.Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma..J Hepatol2019;70:449-57 PMCID:PMC6380944

[144] Jiang SS,Zhang YJ,Zhou ZG.A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma..Oncotarget2015;6:41339-49 PMCID:PMC4747409

[145] Takayama T,Makuuchi M,Kosuge T.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial..Lancet2000;356:802-7

[146] Zhou G,Boor PPC,Schutz H.Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating t cells in hepatocellular carcinomas..Gastroenterology2017;153:1107-19.e10

[147] Mossanen JC,Wehr A,Liepelt A.CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4(+) T-cell-dependent control of senescence..Gastroenterology2019;156:1877-89.e4

[148] Kamiya T,Campana D.Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma..Cancer Immunol Res2016;4:574-81

[149] Tan S,Wang Z,Du X.Tim-3 hampers tumor surveillance of liver resident and conventional NK cells by disrupting PI3K signaling..Cancer Res2020;80:1130-42